First-Line Treatment for Systemic Lupus Erythematosus
All patients with systemic lupus erythematosus should receive hydroxychloroquine at a maximum dose of 5 mg/kg actual body weight (typically 200–400 mg daily) as the universal foundation of therapy, combined with glucocorticoids only when clinically necessary and at the lowest effective dose. 1, 2, 3
Universal Foundation Therapy
Hydroxychloroquine (Mandatory for All Patients)
Hydroxychloroquine must be prescribed to every SLE patient unless absolutely contraindicated because it reduces disease activity, prevents flares, decreases organ damage accrual, and significantly reduces mortality. 2, 4, 5, 3
The maximum dose is 5 mg/kg of actual body weight per day—not ideal body weight—to minimize retinal toxicity risk while maintaining therapeutic efficacy. 2, 4, 3
Ophthalmological screening is mandatory at baseline, after 5 years of continuous use, then annually thereafter using visual field examination and/or spectral domain optical coherence tomography. 2, 4
Hydroxychloroquine blood concentrations can be measured to assess adherence when treatment response appears inadequate. 4
Non-Pharmacological Measures (Essential Adjuncts)
Strict photoprotection with broad-spectrum sunscreen (SPF ≥50–60) must be implemented for all patients, as ultraviolet exposure triggers cutaneous and systemic flares. 2, 6
Smoking cessation is mandatory because tobacco use reduces hydroxychloroquine efficacy and worsens both cutaneous and systemic disease. 2, 6
Calcium 1000–1500 mg plus vitamin D 800–1000 IU daily should be prescribed for all patients receiving glucocorticoids to protect bone health. 2
Glucocorticoid Strategy (When Clinically Required)
Acute/Severe Disease Presentation
For organ-threatening manifestations, administer intravenous methylprednisolone 250–1000 mg daily for 1–3 consecutive days as pulse therapy, followed by oral prednisone 0.3–0.5 mg/kg/day (lower than historical 0.5–1 mg/kg/day based on recent evidence). 2, 4, 3
This pulse-then-taper approach provides rapid disease control while enabling lower cumulative oral steroid exposure compared to high-dose oral monotherapy. 2, 3
Glucocorticoid Tapering Goals (Critical to Prevent Toxicity)
Rapidly taper to ≤7.5 mg/day prednisone equivalent within 3–6 months of disease control, as doses above this threshold markedly increase the risk of irreversible organ damage, infections, osteonecrosis, and mortality. 2, 4, 3
The long-term maintenance target is <5 mg/day prednisone equivalent, with complete withdrawal whenever disease control permits. 2, 4, 3
Chronic glucocorticoid therapy must never exceed 7.5 mg/day because higher doses are the principal driver of steroid-related toxicity and damage accrual. 2, 4
Treatment Goals (Treat-to-Target Approach)
The primary therapeutic objective is to achieve remission (no clinical activity without glucocorticoids or immunosuppressants) or lupus low disease activity state (LLDAS), defined as SLEDAI ≤4, physician global assessment ≤1, and prednisone ≤7.5 mg/day on well-tolerated immunosuppressants. 2, 4, 3
Both remission and LLDAS show comparable outcomes in preventing organ damage and flares, though remission may have slightly lower damage accrual. 4
Assess disease activity at every visit using validated indices (SLEDAI, BILAG, or ECLAM) along with monitoring anti-dsDNA antibodies, complement levels (C3, C4), complete blood count, serum creatinine, proteinuria, and urine sediment. 2, 6, 3
When to Add Immunosuppressive Therapy
Immunosuppressive agents should be added promptly when disease cannot be controlled with hydroxychloroquine and low-dose glucocorticoids alone, or when prednisone cannot be tapered below 7.5 mg/day within 3–6 months. 2, 3
Early initiation of immunosuppressants is essential for enabling rapid glucocorticoid tapering and preventing steroid-related toxicity. 2, 3
First-Line Immunosuppressive Options (Organ-Specific)
Methotrexate 15–25 mg orally once weekly is recommended for predominant cutaneous and articular manifestations. 2, 3
Azathioprine 1–2.5 mg/kg/day is appropriate for maintenance therapy and is particularly suitable for women planning pregnancy. 2, 3
Mycophenolate mofetil 2–3 g/day in divided doses is indicated for moderate multisystem disease (excluding neuropsychiatric involvement) and is the preferred agent for lupus nephritis. 2, 3
Cyclophosphamide (low-dose IV 500 mg every 2 weeks × 6 doses) is reserved for severe organ-threatening or life-threatening manifestations, especially renal, cardiopulmonary, or neuropsychiatric disease. 2, 3
Critical Pitfalls to Avoid
Do not maintain chronic oral prednisone >7.5 mg/day, as this is the principal driver of steroid-related toxicity and irreversible organ damage. 2, 4
Do not delay initiation of immunosuppressive agents; early use is essential for enabling rapid steroid tapering and preventing long-term toxicity. 2, 3
Do not omit hydroxychloroquine unless there is an absolute contraindication—its continued use is critical for all patients regardless of disease activity or other therapies. 2, 5, 3
Do not start with high-dose oral prednisone (1 mg/kg/day) alone; instead, use methylprednisolone pulses followed by lower oral doses (0.3–0.5 mg/kg/day) for better efficacy and lower toxicity. 2, 4
Do not use NSAIDs chronically, as they raise the risk of renal toxicity, cardiovascular events, and gastrointestinal bleeding in SLE patients. 2
Monitoring for Comorbidities and Complications
SLE patients have a 5-fold increased mortality risk; screen aggressively for infections, cardiovascular disease, hypertension, diabetes, dyslipidemia, osteoporosis, avascular necrosis, and malignancies (especially non-Hodgkin lymphoma). 2, 6
Cardiovascular risk assessment should be performed every 6–12 months, with aggressive treatment (statins, antihypertensives) when indicated. 2
For patients with antiphospholipid antibodies (especially high-risk profiles with persistently positive medium/high titers or multiple positivity), consider low-dose aspirin for primary thrombosis prevention, particularly in those with additional cardiovascular risk factors. 4, 6